Literature DB >> 7966418

Analysis of the first-year cost of a prostate cancer screening and treatment program in the United States.

W L Lubke1, S A Optenberg, I M Thompson.   

Abstract

Entities:  

Mesh：

Year:  1994        PMID： 7966418     DOI： 10.1093/jnci/86.23.1790

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  5 in total

1.  Approaches to missing data inference results from CaPSURE: an observational study of patients with prostate cancer.

Authors:  D P Lubeck; D J Pasta; S C Flanders; J M Henning
Journal:  Pharmacoeconomics       Date:  1999-02       Impact factor: 4.981

2.  The clinical burden of prostate cancer in Canada: forecasts from the Montreal Prostate Cancer Model.

Authors:  S A Grover; L Coupal; H Zowall; R Rajan; J Trachtenberg; M Elhilali; M Chetner; L Goldenberg
Journal:  CMAJ       Date:  2000-04-04       Impact factor: 8.262

3.  The economic burden of prostate cancer in Canada: forecasts from the Montreal Prostate Cancer Model.

Authors:  S A Grover; L Coupal; H Zowall; R Rajan; J Trachtenberg; M Elhilali; M Chetner; L Goldenberg
Journal:  CMAJ       Date:  2000-04-04       Impact factor: 8.262

4.  Prostate cancer screening (United States).

Authors:  J W Waterbor; A J Bueschen
Journal:  Cancer Causes Control       Date:  1995-05       Impact factor: 2.506

Review 5.  Cost analysis of screening for, diagnosing, and staging prostate cancer based on a systematic review of published studies.

Authors:  Donatus U Ekwueme; Leonardo A Stroud; Yanjing Chen
Journal:  Prev Chronic Dis       Date:  2007-09-15       Impact factor: 2.830
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.